Et-29
Based on 2 publication(s) in Google Scholar
Et-29 (NRD167) is a selective SIRT5 inhibitor. Et-29 increases the levels of total protein succinylation and citrate synthase succinylation in cells. Et-29 reduces serum CTX-I levels and blocks Ferroptosis by downregulating the SIRT5/ACSL4/LPCAT3/ALOX15 axis and restoring antioxidant defense. Et-29 decreases bone resorption and improves trabecular bone mass and microarchitecture. Et-29 is applicable for research related to osteoporosis and hepatocellular carcinoma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.89%
- No. CAS: 2166487-23-4
- Fòrmula: C34H46N6O6S
- Peso molecular:666.83
-
Almacenamiento:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-15452
SelisistatSirT1/Sir2 Inhibitor -
HY-112634
SIRT5 inhibitor 1Sirtuin Inhibitor -
HY-160818
MC3138SIRT5 Inhibitor -
HY-112587
MC3482Sirtuin Inhibitor -
HY-16691
AK-7Sirtuin Inhibitor -
HY-100591
SirReal2Sirt2 Inhibitor -
HY-B0150
NicotinamideSIRT Inhibitor -
HY-15262
SRT 2104SIRT1 Activator -
HY-107454
OSS_128167SIRT6 Inhibitor -
HY-100591R
SirReal2 (Standard)Sirt2 Inhibitor -
HY-108331
3-TYPSIRT3 Inhibitor -
HY-101278
ThiomyristoylSIRT2 Inhibitor
Publications Citing Use of MedChemExpress (MCE) Et-29
More
Actividad biológica
Descripciòn
|
ACSL4 |
SIRT5 |
In Vitro
ET-29 (40 μM; 24 h) reverses Arachidonic acid (HY-109590)-induced dysregulation of the SIRT5-ACSL4/LPCAT3/ALOX15 ferroptosis pathway in SK-HEP-1 and Hepa1-6 cells, restoring GPX4 and xCT expression toward control levels[3].
ET-29 (40 μM; 24 h) attenuates multiple ferroptosis-associated phenotypes induced by arachidonic acid in SK-HEP-1 and Hepa1-6 cells, including iron accumulation, ROS elevation, lipid peroxidation, and mitochondrial depolarization, while exhibiting no significant effect on these parameters under basal conditions[3].
Inhibition of SIRT5 by Et-29 increases both global protein succinylation and citrate synthase succinylation in HepG2 hepatocellular carcinoma cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SK-HEP-1 human hepatocellular carcinoma cells, Hepa1-6 murine hepatoma cells
-
Concentration:40 μM (alone); 40 μM (co-treatment with 30 μM AA, added 1 hour prior)
-
Incubation Time:24 h
-
Result:Showed no significant alteration of the protein expression levels of SIRT5, ACSL4, LPCAT3, ALOX15, GPX4, or xCT compared with control cells when administered alone.
Markedly reversed the AA-induced upregulation of SIRT5, ACSL4, LPCAT3, and ALOX15, as well as the AA-induced downregulation of GPX4 and xCT, as confirmed by semiquantitative band intensity analysis.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:OVX-induced osteoporosis[1]
-
Dosage:Not specified
-
Administration:i.p.; every other day; 5 weeks
-
Result:Significantly decreased the serum level of CTX-I.
Improved trabecular bone microstructure.
Significantly increased trabecular bone vBMD, BV/TV, BS/TV, and Tb.N values, but no significant improvement was observed in cortical bone microstructural parameters.
Chemical Information
-
No. CAS 2166487-23-4
-
Appearance Solid
-
Peso molecular 666.83
-
Fòrmula C34H46N6O6S
-
Color White to off-white
-
SMILES
O=C(OCC1=CC=CC=C1)N[C@@H](CCCCNC(NCCC(OCC)=O)=S)C(N[C@H](C(NC(C)C)=O)CC2=CNC3=CC=CC=C23)=O
-
Synonyms
NRD167
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Acetylation of GPRC5A at Lys348 facilitates cisplatin resistance and promotes the recurrence and poor prognosis in ovarian cancer. [Abstract]2026 May:362:152113. PMID: 42009151 -
bioRxiv
2023 May 9:2023.05.08.539908. PMID: 37215033
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (149.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (3.75 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
Protein Extraction
Protein extraction uses physical, chemical or biological methods, such as ultrasonic disruption, salting out, cell lysis, electrophoresis, etc., to destroy the cell membrane structure and to separate the proteins from different components according to their characteristics.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Osteoclast differentiation from monocyte/macrophage precursors
Osteoclast differentiation is an in vitro induction assay in which monocyte/macrophage-lineage precursors are exposed to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), generating multinucleated osteoclasts that are commonly identified by tartrate-resistant acid phosphatase (TRAP) staining and functionally confirmed by resorption pits on dentin, bone, or mineralized substrates. M-CSF supports survival and expansion of osteoclast precursors, while RANKL binding to RANK drives osteoclast commitment, fusion, maturation, and resorptive function; osteoprotegerin inhibits this pathway by binding RANKL and preventing RANK activation. The main readouts are the number of TRAP-positive multinucleated cells, formation of F-actin rings, and resorbed surface area; TRAP-positive multinucleated cells indicate osteoclast differentiation, whereas pit formation on dentin, bone, or mineralized coating indicates functional bone-resorbing activity.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[2]. Rajabi N, et al. Mechanism-Based Inhibitors of the Human Sirtuin 5 Deacylase: Structure-Activity Relationship, Biostructural, and Kinetic Insight. Angewandte Chemie (International ed. in English). 2017 Nov 20;56(47):14836-14841. [Content Brief]
[3]. Xue P, et al. Arachidonic acid induces ferroptosis in hepatocellular carcinoma via the SIRT5-ACSL4/LPCAT3/ALOX15 axis, leading to lipid peroxidation and mitochondrial dysfunction. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2025 Nov 25;148:157450. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4996 mL | 7.4982 mL | 14.9963 mL | 37.4908 mL |
| 5 mM | 0.2999 mL | 1.4996 mL | 2.9993 mL | 7.4982 mL | |
| 10 mM | 0.1500 mL | 0.7498 mL | 1.4996 mL | 3.7491 mL | |
| 15 mM | 0.1000 mL | 0.4999 mL | 0.9998 mL | 2.4994 mL | |
| 20 mM | 0.0750 mL | 0.3749 mL | 0.7498 mL | 1.8745 mL | |
| 25 mM | 0.0600 mL | 0.2999 mL | 0.5999 mL | 1.4996 mL | |
| 30 mM | 0.0500 mL | 0.2499 mL | 0.4999 mL | 1.2497 mL | |
| 40 mM | 0.0375 mL | 0.1875 mL | 0.3749 mL | 0.9373 mL | |
| 50 mM | 0.0300 mL | 0.1500 mL | 0.2999 mL | 0.7498 mL | |
| 60 mM | 0.0250 mL | 0.1250 mL | 0.2499 mL | 0.6248 mL | |
| 80 mM | 0.0187 mL | 0.0937 mL | 0.1875 mL | 0.4686 mL | |
| 100 mM | 0.0150 mL | 0.0750 mL | 0.1500 mL | 0.3749 mL |
Et-29 Related Classifications
HY-145651 Related Classifications
Powered by Bioz